BFEC
CCXI

Benjamin F. Edwards & Company’s ChemoCentryx, Inc. CCXI Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-104
Closed -$2K – 1795
2021
Q3 		$2K Hold
104
– – ﹤0.01% 1657
2021
Q2 		$1K Hold
104
– – ﹤0.01% 1667
2021
Q1 		$5K Hold
104
– – ﹤0.01% 1522
2020
Q4 		$6K Buy
+104
New +$5.95K ﹤0.01% 1384

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Benjamin F. Edwards & Company's CCXI Position: Q4 2021 in Review

Benjamin F. Edwards & Company sold out of ChemoCentryx, Inc. (CCXI) in Q4 2021, closing a stake of 104 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in CCXI in Q4 2020 and held it in 4 quarters. The position peaked at $6K in Q4 2020. 190 funds tracked by Wall St. Rank hold CCXI as of Q4 2021.

  • Benjamin F. Edwards & Company reported no remaining ChemoCentryx, Inc. position as of Q4 2021 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 104 ChemoCentryx, Inc. shares in Q4 2021, an estimated $2K.
  • Benjamin F. Edwards & Company first reported a position in ChemoCentryx, Inc. in Q4 2020 and held it in 4 quarters.
  • Benjamin F. Edwards & Company's ChemoCentryx, Inc. position peaked at $6K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2021, filed 7 Feb 2022.